Alamar Biosciences Launches NULISAseq Inflammation Panel AQ, Setting New Standards in Proteomics

Alamar Biosciences Introduces the NULISAseq Inflammation Panel AQ

Alamar Biosciences has made a significant advancement in the field of precision proteomics with the introduction of its new NULISAseq™ Inflammation Panel AQ. This innovative tool is designed to enhance the capability of researchers in profiling the immune response effectively during clinical studies. With this launch, Alamar aims to provide extensive coverage and exceptional precision, setting a new benchmark in the quantitative assessment of disease biomarkers.

The NULISAseq Inflammation Panel AQ enables the detection of over 150 critical protein biomarkers from a single sample, allowing researchers to gain insights into disease progression and therapeutic responses. The utility of this panel lies in its high sensitivity, which is essential for identifying subtle immune changes from normal to disease states. The tool ensures a >99% quantification accuracy in normal samples, allowing researchers to monitor even minor deviations effectively and accurately, crucial for high-stakes clinical environments.

Key Features and Benefits

1. Unmatched Sensitivity: The panel facilitates the detection of immune response changes with incredible sensitivity, affording researchers the opportunity to identify early signs of disease or monitor treatment efficacy reliably.
2. Broad Dynamic Range: Featuring a dynamic range that spans over nine logarithmic units, the NULISAseq Inflammation Panel AQ provides capabilities for simultaneous quantification of both high- and low-abundance proteins. This comprehensive approach ensures thorough data acquisition from clinical samples.
3. High Reproducibility: Achieving a mean coefficient of variation (CV) of less than 10%, the panel guarantees consistent and reliable results across extensive clinical studies, reinforcing confidence in research findings.

The technology behind the NULISAseq Inflammation Panel AQ is grounded in Alamar's proprietary NULISA™ approach. This method integrates a patented sequential immunocomplex capture and release mechanism with cutting-edge next-generation sequencing to facilitate multiplexed, high-sensitivity protein analysis. Notably, utilizing only 10μL of sample (with a 25μL input), this tool addresses challenges often associated with sample limitations, making it ideally suited for research in oncology, autoimmune disorders, and infectious diseases.

Dr. Yuling Luo, Chairman and CEO of Alamar Biosciences, expressed his enthusiasm, stating, "The NULISAseq Inflammation Panel AQ is the largest panel for absolute quantification available and represents a major leap forward in precision proteomics. Its unprecedented sensitivity and dynamic range empower researchers to explore immune system intricacies, thus fostering advancements in our understanding of health and disease."

In summary, the NULISAseq Inflammation Panel AQ not only enhances the existing repertoire of proteomics tools available to researchers but also embodies a transformative shift in how immune responses can be monitored and quantified in clinical research settings. This groundbreaking panel aims to aid researchers significantly in discovering critical disease signatures and developing therapeutic strategies tailored to patient needs. For more insights about the NULISAseq Inflammation Panel AQ, visit alamarbio.com/inflamAQ.

Alamar Biosciences operates with a strong vision of utilizing precision proteomics to facilitate early disease detection. Their proprietary NULISA™ technology, complemented by the ARGO™ HT System, aims to achieve unmatched sensitivity in protein detection, further establishing the company as a leader in this rapidly evolving field.